BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 23941829)

  • 1. NAFLD leads to liver cancer: do we have sufficient evidence?
    Duan XY; Zhang L; Fan JG; Qiao L
    Cancer Lett; 2014 Apr; 345(2):230-4. PubMed ID: 23941829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-viral causes of liver cancer: does obesity led inflammation play a role?
    Alzahrani B; Iseli TJ; Hebbard LW
    Cancer Lett; 2014 Apr; 345(2):223-9. PubMed ID: 24007864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma: fertile soil.
    Torres DM; Harrison SA
    Semin Liver Dis; 2012 Feb; 32(1):30-8. PubMed ID: 22418886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative etiological role of prior hepatitis B virus infection and nonalcoholic fatty liver disease in the development of non-B non-C hepatocellular carcinoma in a hepatitis B-endemic area.
    Cho EJ; Kwack MS; Jang ES; You SJ; Lee JH; Kim YJ; Yoon JH; Lee HS
    Digestion; 2011; 84 Suppl 1():17-22. PubMed ID: 22156481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH.
    Salomao M; Yu WM; Brown RS; Emond JC; Lefkowitch JH
    Am J Surg Pathol; 2010 Nov; 34(11):1630-6. PubMed ID: 20975341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HCC and NASH: how strong is the clinical demonstration?
    Rosmorduc O; Fartoux L
    Clin Res Hepatol Gastroenterol; 2012 Jun; 36(3):202-8. PubMed ID: 22326764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play.
    Charrez B; Qiao L; Hebbard L
    World J Gastroenterol; 2016 Feb; 22(8):2494-502. PubMed ID: 26937137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma.
    Kutlu O; Kaleli HN; Ozer E
    Can J Gastroenterol Hepatol; 2018; 2018():8543763. PubMed ID: 30228976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocarcinogenesis in non-alcoholic fatty liver disease in Japan.
    Tokushige K; Hashimoto E; Kodama K
    J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():88-92. PubMed ID: 24251711
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
    Zoller H; Tilg H
    Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis.
    Ascha MS; Hanouneh IA; Lopez R; Tamimi TA; Feldstein AF; Zein NN
    Hepatology; 2010 Jun; 51(6):1972-8. PubMed ID: 20209604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development.
    Jiang CM; Pu CW; Hou YH; Chen Z; Alanazy M; Hebbard L
    World J Gastroenterol; 2014 Nov; 20(44):16464-73. PubMed ID: 25469014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma.
    Cuadrado A; Orive A; García-Suárez C; Domínguez A; Fernández-Escalante JC; Crespo J; Pons-Romero F
    Obes Surg; 2005 Mar; 15(3):442-6. PubMed ID: 15826485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreased immunoexpression of survivin could be a potential marker in human non-alcoholic fatty liver disease progression?
    Stefano JT; de Oliveira CP; Corrêa-Giannella ML; Soares IC; Kubrusly MS; Bellodi-Privato M; de Mello ES; de Lima VM; Carrilho FJ; Alves VA
    Liver Int; 2011 Mar; 31(3):377-85. PubMed ID: 21108736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obesity and liver cancer.
    Vanni E; Bugianesi E
    Clin Liver Dis; 2014 Feb; 18(1):191-203. PubMed ID: 24274874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The epidemiology of nonalcoholic fatty liver disease in adults.
    Clark JM
    J Clin Gastroenterol; 2006 Mar; 40 Suppl 1():S5-10. PubMed ID: 16540768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linking nonalcoholic fatty liver disease to hepatocellular carcinoma: from bedside to bench and back.
    Yilmaz Y; Colak Y; Kurt R; Senates E; Eren F
    Tumori; 2013; 99(1):10-6. PubMed ID: 23548993
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Approach to the diagnosis and treatment of nonalcoholic fatty liver disease.
    Ong JP; Younossi ZM
    Clin Liver Dis; 2005 Nov; 9(4):617-34, vi. PubMed ID: 16207567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NASH and HCC.
    Page JM; Harrison SA
    Clin Liver Dis; 2009 Nov; 13(4):631-47. PubMed ID: 19818310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of hepatocellular carcinoma related genes and metabolites in human nonalcoholic fatty liver disease.
    Clarke JD; Novak P; Lake AD; Shipkova P; Aranibar N; Robertson D; Severson PL; Reily MD; Futscher BW; Lehman-McKeeman LD; Cherrington NJ
    Dig Dis Sci; 2014 Feb; 59(2):365-74. PubMed ID: 24048683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.